Nucleotica Showcases Innovation at MedTech Innovator Asia Pacific 2025 Pitch Finals
Nucleotica is proud to announce its participation in the final pitch event of MedTech Innovator Asia Pacific 2025, the region’s most prestigious accelerator for medical technology startups.
Among a highly selective cohort of global innovators, R&D Director Nina Krylova represented Nucleotica on the virtual stage, presenting the company’s pioneering platform for DNA and RNA diagnostics.
The session brought together leading startups from around the world, specializing in In Vitro Diagnostics, Life Science Tools, Digital Health, SaaS, and Telemedicine. Nucleotica was honored to be one of the few selected from Europe, and to present alongside forward-thinking companies from the U.S., Sweden, Pakistan, and across the Asia-Pacific region.
During her pitch, Nina Krylova introduced Nucleotica’s integrated molecular diagnostics platform, which enables rapid, accurate, and minimally invasive detection of genetic markers in DNA and RNA. Designed for applications in oncology and personalized medicine, the platform leverages proprietary sensor technologies and robust data processing capabilities to deliver high-precision results from even challenging clinical samples.
“It was a privilege to present our technology to such a respected panel and peer group,” said Nina Krylova. “Our goal is to bring next-generation diagnostics into everyday clinical practice — and this event was a valuable step in building global partnerships to make that happen.”
The pitch finals were evaluated by an esteemed group of judges, including investors, corporate leaders, and healthcare experts. The top 20 companies selected for the MedTech Innovator Asia Pacific 2025 Accelerator Program will be announced at the end of May.
